These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. How Are Retailers Describing Delta-8 THC?A Mixed-Methods Study in Fort Worth, Texas. LoParco CR; Olsson SE; Greene KM; Livingston MD; Henry D; Trangenstein PJ; Walker A; Rossheim ME J Stud Alcohol Drugs; 2023 Mar; 84(2):298-302. PubMed ID: 36971730 [TBL] [Abstract][Full Text] [Related]
5. Derived psychoactive cannabis products and 4/20 specials: An assessment of popular brands and retail price discounts in Fort Worth, Texas, 2023. Rossheim ME; LoParco CR; Berg CJ; Tillett KK; Trangenstein PJ; Henry D; Yockey RA; Livingston MD; Jernigan DH; Sussman SY Drug Alcohol Depend; 2024 Mar; 256():111119. PubMed ID: 38350186 [TBL] [Abstract][Full Text] [Related]
6. Kratom availability in California vape shops. Bowdring MA; Leas EC; Vishwakarma M; Schleicher NC; Prochaska JJ; Henriksen L Prev Med Rep; 2023 Oct; 35():102380. PubMed ID: 37680858 [TBL] [Abstract][Full Text] [Related]
7. Cannabinoid Content and Label Accuracy of Hemp-Derived Topical Products Available Online and at National Retail Stores. Spindle TR; Sholler DJ; Cone EJ; Murphy TP; ElSohly M; Winecker RE; Flegel RR; Bonn-Miller MO; Vandrey R JAMA Netw Open; 2022 Jul; 5(7):e2223019. PubMed ID: 35857320 [TBL] [Abstract][Full Text] [Related]
8. Examining the Psychoactive Differences between Kratom Strains. Huisman G; Menke M; Grundmann O; Schreiber R; Mason N Int J Environ Res Public Health; 2023 Jul; 20(14):. PubMed ID: 37510657 [TBL] [Abstract][Full Text] [Related]
9. Exploring the self-reported motivations of kratom ( Grundmann O; Veltri CA; Morcos D; Knightes D; Smith KE; Singh D; Corazza O; Cinosi E; Martinotti G; Walsh Z; Swogger MT Am J Drug Alcohol Abuse; 2022 Jul; 48(4):433-444. PubMed ID: 35389321 [No Abstract] [Full Text] [Related]
10. A Preliminary Inventory of Kratom Prevete E; Catalani V; Singh D; Kuypers KPC; Theunissen EL; Townshend HD; Banayoti H; Ramaekers JG; Pasquini M; Corazza O J Psychoactive Drugs; 2024; 56(4):485-495. PubMed ID: 37702482 [TBL] [Abstract][Full Text] [Related]
11. Prevalence and description of kratom (Mitragyna speciosa) use in the United States: a cross-sectional study. Schimmel J; Amioka E; Rockhill K; Haynes CM; Black JC; Dart RC; Iwanicki JL Addiction; 2021 Jan; 116(1):176-181. PubMed ID: 32285981 [TBL] [Abstract][Full Text] [Related]
12. For Better or Worse: Self-reported Changes in Kratom and Other Substance Use as a Result of the COVID-19 Pandemic. Rogers JM; Smith KE; Schriefer D; Epstein DH Subst Abuse; 2022; 16():11782218221123977. PubMed ID: 36199697 [TBL] [Abstract][Full Text] [Related]
13. Polysubstance use profiles among US adults using Kratom (Mitragyna speciosa): A latent class analysis using The National Survey on Drug Use and Health (NSDUH). Falise AM; Hoeflich CC; Nutley SK; Lopez-Quintero C; Striley CW Am J Addict; 2023 Jan; 32(1):76-80. PubMed ID: 36222599 [TBL] [Abstract][Full Text] [Related]
14. Following "the Roots" of Kratom (Mitragyna speciosa): The Evolution of an Enhancer from a Traditional Use to Increase Work and Productivity in Southeast Asia to a Recreational Psychoactive Drug in Western Countries. Cinosi E; Martinotti G; Simonato P; Singh D; Demetrovics Z; Roman-Urrestarazu A; Bersani FS; Vicknasingam B; Piazzon G; Li JH; Yu WJ; Kapitány-Fövény M; Farkas J; Di Giannantonio M; Corazza O Biomed Res Int; 2015; 2015():968786. PubMed ID: 26640804 [TBL] [Abstract][Full Text] [Related]
15. A Cross-sectional Analysis of Socio-spatial Patterning of Tobacco Retail in Shanghai, China. Zheng C; Feng Z; Pearce J Nicotine Tob Res; 2022 Nov; 24(12):2018-2025. PubMed ID: 35777980 [TBL] [Abstract][Full Text] [Related]
16. Commercial Delta-8 THC Products: an Analysis of Content and Labeling. Kaczor EE; Greene K; Babu KM; Berthold EC; Sharma A; Carreiro SP J Med Toxicol; 2024 Jan; 20(1):31-38. PubMed ID: 37917314 [TBL] [Abstract][Full Text] [Related]
17. Assessing the quality of information provided on websites selling Kratom (Mitragyna speciosa) to consumers in Canada. Ng JY; Ans M; Marwaha A Subst Abuse Treat Prev Policy; 2021 Mar; 16(1):23. PubMed ID: 33741009 [TBL] [Abstract][Full Text] [Related]
18. A validated method for the quantification of mitragynine in sixteen commercially available Kratom (Mitragyna speciosa) products. Fowble KL; Musah RA Forensic Sci Int; 2019 Jun; 299():195-202. PubMed ID: 31059866 [TBL] [Abstract][Full Text] [Related]
19. Correlations of kratom (Mitragyna speciosa Korth.) tea bag preparations and reported pharmacological effects. Grundmann O; Hill K; Al Barzanji E; Hazrat NG; Kaur G; Negeve RE; Shade S; Weber S; Veltri CA J Ethnopharmacol; 2023 Dec; 317():116779. PubMed ID: 37364801 [TBL] [Abstract][Full Text] [Related]
20. Correlations of kratom (Mitragyna speciosa Korth.) use behavior and psychiatric conditions from a cross-sectional survey. Grundmann O; Veltri CA; Morcos S; Smith KE; Singh D; Corazza O; Cinosi E; Martinotti G; Walsh Z; Swogger MT Exp Clin Psychopharmacol; 2023 Oct; 31(5):963-977. PubMed ID: 36634016 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]